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of urokinase, we sought to determine whether these per-
ceptions were justified or whether there were other factors
that affected the results of earlier studies in which t-PA was
used to treat vascular occlusions. Some earlier studies
involving t-PA used doses of 5 mg/h and higher, com-
pared with the present study in which the highest dose
employed was 2 mg/h, with a maximum dose of 100 mg
total. In addition, there have been significant advances
made in the technical aspects of administration of lytic
agents, resulting in improved outcomes and shorter infu-
sion times. This study was undertaken to determine
whether urokinase and t-PA may in fact be equivalent with
regard to safety and efficacy if used in the setting of cur-
rent interventional techniques and lower dosing.
PATIENTS AND METHODS
After urokinase became unavailable in November
1998, patients presenting with acute arterial occlusion
(AAO) or acute venous occlusion (AVO) at our institution
were treated with t-PA. This group of patients, treated
between November 1998 and August 2000, was com-
pared in retrospective fashion with the cohort of patients
treated with urokinase for the 12-month period
(November 1997 to November 1998) immediately pre-
ceding. Between November 1997 and August 2000, no
substantive changes occurred with regard to the technique
Urokinase has been the agent of choice in the treat-
ment of acute arterial and venous occlusions in most med-
ical centers for the past decade.1-3 The removal of
urokinase from the market in November 1998 has forced
interventional radiologists and vascular surgeons to use
alternative thrombolytic agents in the treatment of acute
peripheral vascular thrombosis. Previous experience with
tissue plasminogen activator (t-PA) has resulted in the per-
ception that this agent may be as effective as urokinase but
is associated with a higher rate of major bleeding compli-
cations, especially the most feared complication of
intracranial hemorrhage. Given the current unavailability
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Objective: The purposes of this study were to evaluate the safety and efficacy of limited-dose tissue plasminogen activa-
tor (t-PA) in patients with acute vascular occlusion and to compare these results with those obtained in equivalent
patients receiving urokinase.
Methods: We compared the results of 60 patients receiving catheter-directed urokinase from November 1997 to
November 1998 (240,000 units/h × 4 h, 120,000 units/h thereafter for a maximum of 48 h) with those of 45 patients
receiving catheter-directed t-PA from November 1998 to August 2000 (2 mg/h, total dose ≤100 mg) for acute arter-
ial occlusion (AAO) and acute venous occlusion (AVO). Interventional approaches such as cross-catheter and coaxial
techniques were used to reduce the dose of lytic agent needed to achieve pre–lysis-treatment goals (eg, complete lysis
of all thrombus/unmasking graft stenosis or establishing outflow target). Statistical analysis was performed using
Student t test and Fisher exact test.
Results: The urokinase and t-PA groups were comparable with regard to age, comorbidities (coronary artery disease,
hypertension, diabetes, renal insufficiency, smoking), duration of ischemic or occlusive symptoms, location of occlusive
process, pretreatment with warfarin, and thrombotic versus embolic and native versus graft occlusion in patients with
AAO. In patients with AAO and in those with AVO, t-PA was equivalent to or better than urokinase with regard to
percent of clot lysis, incidence of major bleeding complications, limb salvage, and mortality. Achievement of pretreat-
ment goals (arterial patients only) was 50% for urokinase patients and 76% for t-PA patients (P = .02). Analysis of suc-
cess in individual pretreatment-goal achievement showed urokinase and t-PA to be equivalent in unmasking stenoses
(85% and 84%, respectively; P = NS), whereas t-PA was superior to urokinase in the more critical task of establishing
run-off (39% versus 81% for urokinase and t-PA, respectively; P = .001). Additional interventions, either endovascular
or surgical, were required in 60% and 51% (P = NS) of patients receiving urokinase and t-PA, respectively, for AAO,
and in 54% and 62% (P = NS) of patients receiving urokinase and t-PA, respectively, for AVO.
Conclusions: Limited-dose t-PA is a safe and effective therapy for AAO and AVO when administered by experienced
teams using innovative but well-established interventional techniques. (J Vasc Surg 2001;34:854-9.)
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of administration of thrombolytic agent. Results in
patients treated for AAO and AVO were analyzed sepa-
rately.
Acute arterial occlusions
Retrospective chart review was conducted on 36
patients receiving urokinase for AAO and 37 patients
receiving t-PA for AAO at Strong Memorial Hospital
between November 1997 and August 2000.
The groups were equivalent with regard to age, sex,
comorbidities, pretreatment with warfarin, duration of
occlusion, nature and severity of ischemic symptoms, loca-
tion of occlusion, presence of native versus graft occlusion,
presence of thrombotic versus embolic occlusion (Tables
Ia, IIa). In the urokinase group, 17 of the 22 grafts were
autogenous and 5 were prosthetic, whereas in the t-PA
group, 20 of the 27 grafts were autogenous and 7 were
prosthetic. In the urokinase group, there were 14
femoropopliteal grafts, 4 femorotibial grafts, 2 inflow con-
duits, and 2 patients with both inflow and outflow con-
duits. In the t-PA group, there were 15 femoropopliteal
grafts, 7 femorotibial grafts, 3 inflow conduits, and 2
patients with both inflow and outflow conduits.
Indications for thrombolysis. Patients with acute
(14 days or less) Society for Vascular Surgery/International
Society for Cardiovascular Surgery class IIa or IIb
ischemia4 caused by thrombotic or embolic occlusion of a
native artery or bypass graft were considered eligible for
thrombolysis.
Exclusion criteria. Exclusion criteria included any
history of major hemorrhage involving the brain or gas-
trointestinal tract, pregnancy, age of less than 18 years,
bleeding diathesis (excluding pharmacologic), recent (<14
days) surgery or trauma, inability to traverse the clot with
a guidewire, and embolic occlusion of the common
femoral artery in the absence of peripheral vascular disease.
Techniques of administration. Diagnostic arteriog-
raphy was performed via the contralateral extremity, or, if
this was not possible, from the axillary approach. Lytic
agent was administered directly into the thrombus in all
instances, with use of coaxial catheter systems and cross-
catheter techniques when necessary. Pulse-spray catheter
techniques were not used routinely.
Dosing and use of heparin. Urokinase was adminis-
tered at 240,000 units/h for the first 4 hours and reduced
to 120,000 units/h thereafter, for a maximum of 48
hours. The mean total dose of urokinase was 4,676,167
units. t-PA was administered at 2 mg/h for a maximum of
100 mg with no initial bolus and a mean total dose of 51.2
mg. Low-dose intravenous heparin (500 units/h) was
used to prevent pericatheter thrombosis in all patients.
Fibrinogen levels were not routinely monitored,
because it is not the policy at our institution to alter ther-
apy based on fibrinogen values alone. This is based on data
from previous studies demonstrating that fibrinogen levels
correlate poorly with clinical risk of bleeding.3,5,6 The
decision to discontinue thrombolytic therapy was made on
the basis of clinically significant bleeding only.
Efficacy endpoints. The efficacy of the lytic agent
was assessed by determining the percentage of clot lysis
achieved in each patient (percent lysis was estimated by a
single, blinded observer comparing prelysis and postlysis
angiograms and multiplying the length of occlusion by the
vessel diameter), the amount of time required to achieve
complete lysis, 30-day limb salvage and mortality, need for
additional interventions after administration of lytic agent,
and achievement of pretreatment goals. Pretreatment
goals (either complete lysis of all thrombus/unmasking of
underlying stenosis or establishing run-off) were identified
retrospectively in blinded fashion. 
Safety endpoints. The safety of each agent was deter-
mined by establishing the relative incidence of major hem-
orrhage (bleeding requiring transfusion or operative
intervention or that was considered to be life-threaten-
ing), minor hemorrhage (bleeding not meeting the afore-
mentioned criteria, such as local hematoma formation, or
modest bleeding at catheter insertion or remote sites),
intracranial hemorrhage, and allergic reaction.
Table Ia. Patient demographics for arterial occlusions
Agent Age (y) Male (%) CAD (%) Hypertension (%) Diabetes (%) Renal failure (%) Smoking (%) Warfarin (%)
Urokinase (n = 6) 63.9 19 (53) 17 (47) 25 (69) 22 (61) 5 (14) 23 (64) 12 (33)
t-PA (n = 37) 63.7 15 (41) 16 (43) 26 (70) 20 (54) 5 (14) 20 (54) 11 (30)
P value NS NS NS NS NS NS NS NS
CAD, Coronary artery disease.
Table Ib. Patient demographics for venous occlusions
Hypertension Diabetes Renal failure Smoking Warfarin
Agent Age (y) Male (%) CAD (%) (%) (%) (%) (%) (%)
Urokinase (n = 23) 40.1 12 (52) 4 (17 4 (17) 6 (26) 0 4 (17) 7 (30)
t-PA (n = 8) 44.8 4 (50) 1 (12) 2 (25) 1 (12) 0 2 (25) 2 (25)
P value NS NS NS NS NS NS NS
CAD, Coronary artery disease.
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Acute venous occlusions
Charts from 23 patients receiving urokinase and eight
receiving t-PA were reviewed from the same time period
and institution as noted above. The two groups were
equivalent with regard to age, sex, comorbidities, pre-
treatment with warfarin, duration of occlusion, nature and
severity of occlusive symptoms, and location of occlusion
(Tables Ib, IIb).
Indications for thrombolysis. Patients with acute
(14 days of symptoms or less) venous thrombosis (exclud-
ing catheters and arteriovenous fistulae) were considered
eligible for thrombolysis.
Exclusion criteria. The same criteria were applied as
in patients with AAO, with the exception of common
femoral emboli.
Dosing and use of heparin. Dosing and use of
heparin, techniques of administration of lytic agent, and
monitoring of fibrinogen levels were comparable with
those used for patients with AAO. The mean total dose of
urokinase was 4,618,542 units, and the mean total dose of
t-PA was 81.5 mg.
Efficacy endpoints. The efficacy of the lytic agent
was assessed by determining the percentage of clot lysis
achieved in each patient (using analysis of prelysis and
postlysis venograms), the amount of time required to
achieve complete lysis, and the need for additional inter-
ventions after administration.
Safety endpoints. The safety of each agent was deter-
mined by establishing the relative incidence of major and
minor hemorrhage and other criteria outlined previously.
Statistical analysis was performed using the Student two-
tailed t test for continuous variables and the Fisher exact
test for proportions in both groups of patients.
RESULTS
Acute arterial occlusion. There were no significant
differences between the two groups with regard to 30-day
mortality, major and minor hemorrhage, need for addi-
tional intervention, length of stay, and achievement of
individual pretreatment goals (Table III). One major
bleeding event (3%) occurred in each of the groups; in
both cases this was bleeding from a catheter insertion site,
and both patients required operative intervention to cor-
rect the problem. Minor bleeding events occurred in five
of the patients in the t-PA group (14%) and four of the
patients in the urokinase group (11%). Distal emboli were
noted in eight patients receiving urokinase and four
patients receiving t-PA.
Four patients died within 30 days of undergoing
thrombolysis; in the t-PA group, one patient died from an
underlying malignancy, whereas the other patient died of
myocardial infarction that occurred subsequent to bleed-
ing at the catheter insertion site. In the urokinase group
the deaths were caused by myocardial infarction and respi-
ratory failure.
Significant differences were noted between the two
groups with regard to percent lysis, length of infusion,
limb salvage, and combined achievement of either pre-
treatment goal (Table III); t-PA was associated with
shorter infusion time (20.9 hours versus 33.8 hours; P =
.001), decrease in limb loss (8% versus 27%; P = .03), and
increase in pretreatment-goal achievement (76% versus
50%; P = .02). Analysis of success in individual pretreat-
ment-goal achievement showed t-PA and urokinase to be
equivalent in unmasking stenoses (84% and 83%, respec-
tively; P = NS), whereas t-PA was superior to urokinase in
establishing run-off (81% versus 39%; P = .001).
Additional procedures, either operative or interven-
tional, were required in the majority of patients (Table IV).
In the urokinase group, the two additional interventional
procedures required were angioplasty of a stenotic vein
graft lesion and angioplasty of an anastomotic stenosis. The
20 additional operative procedures required in the uroki-
nase patients included 1 femoral artery repair at a catheter
insertion site, 4 inflow procedures, 9 outflow procedures,
Table IIa. Occlusive process in arterial patients
Sx duration Infrainguinal Suprainguinal Thrombosis Embolus Native Graft
Agent (h) (%) (%) (%) (%) (%) (%)
Urokinase (n = 36) 4.9 28 (78) 8 (22) 30 (83) 6 (17) 14 (39) 2 (61)
t-PA (n = 37) 2.9 28 (76) 9 (24) 33 (89) 4 (11) 10 (27) 27 (73)
P value NS NS NS NS NS NS NS
Sx, Symptom.
Table IIb. Occlusive process in venous patients
Upper-extremity Lower-extremity Predisposing
Agent Sx duration (d) thrombosis (%) thrombosis (%) factors (%)
Urokinase (n = 23) 3.5 6 (26) 17 (74) 18 (78)
t-PA (n = 8) 3.9 2 (25) 6 (75) 6 (75)
P value NS NS NS NS
Sx, Symptom.
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3 patch angioplasties of vein graft stenoses, and 3 graft
replacements. In the t-PA group, the two interventional
procedures after lysis included stenting of an iliac (inflow)
stenosis and angioplasty of a vein graft stenosis. The 17
additional operative procedures included 1 femoral artery
repair, 2 inflow procedures, 11 outflow procedures, 2
patch angioplasties, and 2 graft replacements.
Acute venous occlusion. In the group of patients
receiving urokinase, six patients had upper-extremity
symptoms with subclavian vein thrombosis; of these, three
patients had superior vena cava involvement. Seventeen of
the patients in the urokinase group had lower-extremity
symptoms; of these, 12 patients had iliofemoral clot,
including three with inferior vena cava involvement,
whereas five patients had clot limited to the infrainguinal
distribution. In the t-PA group, neither of the two patients
with upper-extremity symptoms and subclavian vein
thrombosis had involvement of the superior vena cava; in
the patients with lower extremity symptoms, three had
iliofemoral involvement, including one with caval throm-
bosis, and three had infrainguinal involvement only.
No significant differences were identified between the
two groups with regard to any of the parameters studied,
although infusion time approached significance (Table
III). There were no incidents of pulmonary embolism in
any of the patients studied. The two episodes of major
bleeding in the urokinase group consisted of a retroperi-
toneal hematoma and catheter insertion site bleeding, and
bleeding from the insertion site developed in one patient
in the t-PA group. None of these patients required opera-
tive correction of the problem.
Additional procedures, either operative or interven-
tional, were required in the majority of patients (Table
IV). These included both procedures to deal with hemor-
rhage from catheter insertion sites and corrective measures
to deal with the underlying problem, such as angioplasty
and stenting of venous stenoses, first rib resection, and
jugular turndown.
DISCUSSION
Until its removal from the marketplace in November
1998, urokinase was the agent of choice in the treatment
of AVO. Its lack of availability mandates objective assess-
ment of all potential options for patients requiring throm-
bolysis. t-PA has been a long-standing alternative to
urokinase but has been less frequently used because of
concerns over excessive bleeding risk. Many of the data on
which these concerns are based, however, are drawn from
studies in which dosing was higher than presently used,
and in which infusions may have been prolonged as a
result of less sophisticated techniques of administration.
Until now, it has not been essential to examine these data
critically, because urokinase was a safe, effective agent with
which practitioners had vast experience. With the lack of
availability of urokinase, it is now necessary to critically
examine these old assumptions about the safety and effi-
cacy of t-PA. Although limited by its retrospective nature,
and although the data on venous occlusions are severely
limited by the low numbers of patients in the t-PA group,
this study attempts to compare the results of low-dose t-
PA and standard-dose urokinase administered at a single
institution over contiguous time periods. By eliminating
variability based on technical advances and dosing, it is
hoped that a more accurate comparison can be drawn
between the safety and efficacy of these two agents than
has been previously available.
The present study demonstrates that t-PA is at least
equivalent to urokinase in the majority of the efficacy para-
meters studied (overall percent lysis, achievement of indi-
vidual pretreatment goals, limb salvage, and infusion time)
and that it is equivalent to urokinase in the two most
Table III. Efficacy outcomes: Arterial and venous patients
PTGs
Infusion Mean % 30-d Unmask Establish
Agent time (h) lysis Limb loss mortality All PTGs stenosis run-off
AAO
Urokinase (n = 36) 33.8 63.7% 10 (28%) 2 (5%) 18 (50%) 30 (83%) 14 (39%)
t-PA (n = 37) 20.9 82.0% 3 (8%) 2 (5%) 28 (76%) 31 (84%) 30 (81%)
P value .001 .03 .03 .02 NS .001
AVO
Urokinase (n = 23) 43 81% 0
t-PA (n = 8) 30 77% 0
P value NS NS
PTGs, Pretreatment goals.
Table IV. Additional interventions required for arterial
and venous occlusions
Interventional Operative 
Agent None (%) procedure (%) procedure (%)
AAO
Urokinase (n = 36) 14 (40) 2 (5) 20 (55)
t-PA (n = 37) 18 (49) 2 (5) 17 (46)
AVO
Urokinase (n = 23) 11 (48) 12 (52) 0
t-PA (n = 8) 3 (37) 4 (50) 1 (12)
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important safety parameters (major bleeding and mortal-
ity). Unfortunately, the relatively small number of patients
included in the study preclude analysis of subgroups such
as diabetic patients versus nondiabetic patients, sex,
thrombotic versus embolic occlusion, characteristics of
occluded conduit, and location of occluded vessel. Future
multicenter trials will be needed to address these issues.
The inclusion of pretreatment goals in our analysis of
successful outcome was undertaken to more specifically
characterize successful lysis. Because thrombolysis is fre-
quently undertaken to improve surgical or interventional
options, rather than to eliminate the need for additional
intervention entirely, we felt that it was important to iden-
tify whether one agent was superior to the other in achiev-
ing this end, rather than simply quantifying percent lysis.
The improved limb salvage in the t-PA group is likely a
major reflection of the higher rate of outflow lysis.
There are some significant pharmacologic differences
between urokinase and t-PA. Urokinase is a serine pro-
tease, an endogenous form of which is present in the
plasma in the form of a proenzyme with a single polypep-
tide chain structure (single-chain urokinase plasminogen
activator or pro-urokinase).7 This latter molecule has been
manufactured by using recombinant technology (obviat-
ing the concerns over viral contamination inherent in the
production of urokinase) and has had promising results in
the intra-arterial treatment of acute stroke.8 However, the
degree of statistical significance achieved in this study was
not sufficient to warrant Food and Drug Administration
approval of the drug. Alteplase is a genetically engineered
recombinant form of the mammalian protease t-PA.9,10 t-
PA is a fibrin-specific agent, whereas urokinase is not11.
Fibrin specificity refers to the ability of an agent to prefer-
entially bind to fibrin-bound plasminogen, as opposed to
free plasminogen. Theoretically, this leads to plasminogen
activation only where it is needed, in the occlusive throm-
bus, as opposed to indiscriminately and systemically, thus
reducing the risk of hemorrhage. However, this potential
benefit has not been observed in clinical practice, because
both fibrin-specific and non–fibrin-specific agents are
associated with systemic consumption of fibrinogen.12
Previous reports investigating the use of t-PA for AAO
give widely varying results, most likely reflective of widely
varying dosing, heparin administration, and catheter tech-
niques. Dosing regimens ranged from 0.02 mg/kg/h to
10 mg/h, with mean total doses ranging from 5 mg to 84
mg. Use of heparin varied as well, from 0 to 1,000
units/h. Reported rates of major hemorrhage varied from
0% to 17%.13-18 In a recently published meta-analysis of
the literature on t-PA and AAO, Semba et al19 conclude
that the risk of bleeding appears to increase with increas-
ing doses of t-PA, that the role of heparin is unclear, both
in terms of safety and efficacy, and that despite the varied
methods used in the different trials, t-PA appears to be
associated with a safety and efficacy profile comparable
with that of urokinase. In another recent retrospective
meta-analysis comparing 472 patients treated for AAOs
with urokinase, t-PA, and reteplase, Ouriel et al20 reported
no difference among the agents with regard to any of the
important safety and efficacy parameters studied, includ-
ing percent lysis, rate of major bleeding, fibrinogen nadir,
and overall clinical success rate.
CONCLUSIONS
Although limited by its retrospective design, the pres-
ent study produced results that are in accordance with the
results of the meta-analysis by Semba et al and the more
recent meta-analysis by Ouriel et al showing that t-PA is a
safe and effective alternative to urokinase in the treatment
of AVO. Because this study is retrospective in nature,
involves consecutive time periods of study, and involves
small numbers of patients, no conclusions can accurately
be made regarding improved safety and efficacy of t-PA
compared with urokinase. Unquestionably, a randomized
controlled trial evaluating t-PA by using standardized dos-
ing techniques and heparin administration is needed to
refine our use of this agent and to further maximize its
safety and efficacy.
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Dr Steven Sparks (San Diego, Calif). I would like to thank
the Society for inviting me to comment on this paper and thank
Dr Shortell for an excellent presentation as well as getting me the
paper well in advance of the meeting.
Today she has presented to us some information about lytic
therapy at the institution she represents, that is well known for
being the leader in lytic therapy both in the grafts and in the
venous system. What this has shown us over a 12-month time
period, a retrospective analysis of urokinase versus a 21-month
time period with t-PA with 36 arterial occlusions with UK and 37
with the t-PA, 23 in the urokinase for the venous and 8 for the t-
PA. The main statistical advantage occurred in the arterial occlu-
sion subgroup where the runoff was better established with the
t-PA. This was trending towards slightly lower lytic therapy time
periods.
I have four questions. Number one: Any analysis of these
four very small groups, has a chance of a type II error built into
the statistics. Do you think this is possible or probable?
Number two: Minor bleeding as the main nuisance in this
procedure and the catastrophic problem with both these agents is
the possibility of intracranial bleed. The overall incidence in the
literature being approximately 1%. Can we really draw that the t-
PA agent is safe when in your own study you had no intracranial
bleeds for either agent?
Number three: Since you decrease not only the t-PA dose but
also the heparin dose, which would you feel is actually primarily
responsible for your decreased bleeding and your decreased com-
plications? 
Number four: Have you or anyone at your institution looked
at the use of lower doses of t-PA, even lower than what you are
currently using? At our own institution, we are down to about
0.02 mg/cc for lysing our grafts and we are actually opening
grafts with as little as 2 mg of total t-PA use.
Thank you.
Dr Cynthia K. Shortell. Thank you, Dr Sparks. With regard
to your first question, certainly I think that this is a very small
group of patients. Particularly the venous group is almost as small
as to be not worth including, and I agree that type II error is cer-
tainly a strong possibility.
With regard to the intracranial hemorrhage issue, I think that
the incidence of ICH remains a major problem for us. It is the
real bugaboo of thrombolytic therapy, and I do not know
whether we can draw any conclusions from this study since there
were no instances of ICH in this study. In my experience, the inci-
dence of ICH is a sporadic event, and I think, as we discussed
informally, may reflect the thrombolytic agent being in the wrong
place at the wrong time, so to speak, while an event is going on
or an unrecognized defect in the brain exists rather than an effect
of the lytic agent itself, although the cardiac literature may belie
this a little bit. In any event, I think the vascular literature sug-
gests that the rate of ICH is probably equivalent for all of the lytic
agents. I do not think we can make any conclusions from this
study about the incidence of ICH.
I agree with you that the reduction in our heparin dose, while
it probably has very little effect on the efficacy end of things, may
have just as much or maybe even more effect on the safety end of
the t-PA patients compared with UK patients, although we used
the same dose of heparin in both groups of patients for the time
period studied. We have actually gone to an even lower dose of
heparin in many patients, sometimes even as low as 250 units
IV/hour in patients undergoing thrombolysis now. I think there
is evidence that this is probably even better than 500.
We have not had a lot of experience with very low dose t-PA.
The little experience that we have has not been all that favorable. We
seem to need that minimum of 0.05 mg/kg/hour in order to gain
efficacy, but we are certainly open to suggestion and will consider the
possibility of using even lower doses of t-PA in the future.
Thank you.
DISCUSSION
